Infanrix Penta

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain)), hepatitis B surface antigen

Available from:

GlaxoSmithKline Biologicals S.A.

ATC code:

J07CA12

INN (International Name):

diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed)

Therapeutic group:

Ваксини

Therapeutic area:

Hepatitis B; Tetanus; Immunization; Whooping Cough; Poliomyelitis; Diphtheria

Therapeutic indications:

Infanrix Penta е показан за първична и бустер ваксинация на кърмачета срещу дифтерия, тетанус, коклюш, хепатит В и полиомиелит.

Product summary:

Revision: 13

Authorization status:

Отменено

Authorization date:

2000-10-23

Patient Information leaflet

                                Лекарствен продукт, който вече не е
разрешен за употреба
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
1
Лекарствен продукт, който вече не е
разрешен за употреба
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Infanrix Penta инжекционна су
спензия
Адсорбирана ваксина срещу дифтерия,
тетанус, коклюш (безклетъчна,
компонентна), хепатит В
(р-ДНК), полиомиелит (инактивирана).
_Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa),
hepatitis B (rDNA) (HBV), _
_poliomyelitis (inactivated) (IPV) vaccine (adsorbed)_
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
1 доза (0,5 m
l) съдържа:
Дифтериен токсоид
_(Diphtheria toxoid)_
1
не по-малко от 30 IU
Тетаничен токсоид
_(Tetanus toxoid)_
1
не по-малко от 40 IU
Антигени на
_ Bordetella pertussis_
Коклюшен токсоид
_(Pertussis toxoid)_
1
25 микрограма
Филаментозен хемаглу
тинин
_(Filamentous Haemagglutinin)_
1
25 микрограма
Пертактин
_(Pertactin)_
1
8 микрограма
Повърхностен антиген на виру
са на хепатит В (Hepatitis B surface antigen)
2,3
10 микрограма
Инактивиран полиовиру
с
_(Poliovirus(inactivated)) _
тип
1 (щам Mahoney)
4
40 D-антигенни единици
тип 2 (щам MEF-1)
4
8 D-антигенни единици
тип 3 (щам Saukett)
4
32 D-антигенни единици
1
адсорбиран върху алуминиев хидроксид
(Al(OH)
3
)
0,5 милиграма Al
3+
2
произведен в дрождеви клетки (
_Saccharomyces cerevisiae_
) чрез рекомбинантна ДНК технология
3
адсорби
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Лекарствен продукт, който вече не е
разрешен за употреба
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
1
Лекарствен продукт, който вече не е
разрешен за употреба
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Infanrix Penta инжекционна су
спензия
Адсорбирана ваксина срещу дифтерия,
тетанус, коклюш (безклетъчна,
компонентна), хепатит В
(р-ДНК), полиомиелит (инактивирана).
_Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa),
hepatitis B (rDNA) (HBV), _
_poliomyelitis (inactivated) (IPV) vaccine (adsorbed)_
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
1 доза (0,5 m
l) съдържа:
Дифтериен токсоид
_(Diphtheria toxoid)_
1
не по-малко от 30 IU
Тетаничен токсоид
_(Tetanus toxoid)_
1
не по-малко от 40 IU
Антигени на
_ Bordetella pertussis_
Коклюшен токсоид
_(Pertussis toxoid)_
1
25 микрограма
Филаментозен хемаглу
тинин
_(Filamentous Haemagglutinin)_
1
25 микрограма
Пертактин
_(Pertactin)_
1
8 микрограма
Повърхностен антиген на виру
са на хепатит В (Hepatitis B surface antigen)
2,3
10 микрограма
Инактивиран полиовиру
с
_(Poliovirus(inactivated)) _
тип
1 (щам Mahoney)
4
40 D-антигенни единици
тип 2 (щам MEF-1)
4
8 D-антигенни единици
тип 3 (щам Saukett)
4
32 D-антигенни единици
1
адсорбиран върху алуминиев хидроксид
(Al(OH)
3
)
0,5 милиграма Al
3+
2
произведен в дрождеви клетки (
_Saccharomyces cerevisiae_
) чрез рекомбинантна ДНК технология
3
адсорби
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 10-07-2013
Public Assessment Report Public Assessment Report Spanish 10-07-2013
Patient Information leaflet Patient Information leaflet Czech 10-07-2013
Public Assessment Report Public Assessment Report Czech 10-07-2013
Patient Information leaflet Patient Information leaflet Danish 10-07-2013
Public Assessment Report Public Assessment Report Danish 10-07-2013
Patient Information leaflet Patient Information leaflet German 10-07-2013
Public Assessment Report Public Assessment Report German 10-07-2013
Patient Information leaflet Patient Information leaflet Estonian 10-07-2013
Public Assessment Report Public Assessment Report Estonian 10-07-2013
Patient Information leaflet Patient Information leaflet Greek 10-07-2013
Public Assessment Report Public Assessment Report Greek 10-07-2013
Patient Information leaflet Patient Information leaflet English 10-07-2013
Public Assessment Report Public Assessment Report English 10-07-2013
Patient Information leaflet Patient Information leaflet French 10-07-2013
Public Assessment Report Public Assessment Report French 10-07-2013
Patient Information leaflet Patient Information leaflet Italian 10-07-2013
Public Assessment Report Public Assessment Report Italian 10-07-2013
Patient Information leaflet Patient Information leaflet Latvian 10-07-2013
Public Assessment Report Public Assessment Report Latvian 10-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-07-2013
Public Assessment Report Public Assessment Report Lithuanian 10-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Hungarian 10-07-2013
Public Assessment Report Public Assessment Report Hungarian 10-07-2013
Patient Information leaflet Patient Information leaflet Maltese 10-07-2013
Public Assessment Report Public Assessment Report Maltese 10-07-2013
Patient Information leaflet Patient Information leaflet Dutch 10-07-2013
Public Assessment Report Public Assessment Report Dutch 10-07-2013
Patient Information leaflet Patient Information leaflet Polish 10-07-2013
Public Assessment Report Public Assessment Report Polish 10-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 10-07-2013
Summary of Product characteristics Summary of Product characteristics Portuguese 10-07-2013
Public Assessment Report Public Assessment Report Portuguese 10-07-2013
Patient Information leaflet Patient Information leaflet Romanian 10-07-2013
Public Assessment Report Public Assessment Report Romanian 10-07-2013
Patient Information leaflet Patient Information leaflet Slovak 10-07-2013
Public Assessment Report Public Assessment Report Slovak 10-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Slovenian 10-07-2013
Public Assessment Report Public Assessment Report Slovenian 10-07-2013
Patient Information leaflet Patient Information leaflet Finnish 10-07-2013
Public Assessment Report Public Assessment Report Finnish 10-07-2013
Patient Information leaflet Patient Information leaflet Swedish 10-07-2013
Public Assessment Report Public Assessment Report Swedish 10-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Norwegian 10-07-2013
Patient Information leaflet Patient Information leaflet Icelandic 10-07-2013
Summary of Product characteristics Summary of Product characteristics Icelandic 10-07-2013

View documents history